| Paris | |
| 0 | |
| High growth fully integrated specialty biopharamaceutical company, recognized for his expertise to develop and market new products via paediatric or orphan registration, especially in the area of neurology and nephrology. | |
| ADV7103 is an innovative product combining two different API, prolonged-release micro-tablets, in order to treat two rare renal tubulopathies. ADV7103 is an innovative fix dose combination that has the triple advantage (i) to be tasteless and easy to swallow by young children, (ii) to reduce side effects at the gastric level and (iii) to require only 2 doses per day for an efficiency of 24 hours. The pivotal phase II / III for the first indication is ongoing, the last patients will be included in the study during January 2016. The phase II/III for the second indication will start in 2016. Both diseases lead to serious complications including lifelong recurrent lithiasis for both targeted diseases as well as long term consequences such as significant effects on growth in children or important various renal dysfunctions. There is no registered treatment for both indications in Europe, nor in the US. The global patient population is about 75 000 patients in Europe and 50.000 patients in the US, with a peak sales potential of respectively 150M and 200M$. |
|
| DELBAERE Sarah | |
| advicenne.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 22 fois.